FDA Gives Approval to Zurzuvae to Ease Postpartum Depression
SATURDAY, Aug. 5, 2023 -- The U.S. Food and Drug Administration on Friday approved a new pill, called zuranolone, that may quickly ease severe postpartum depression and help millions of women regain their emotional equilibrium following... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 5, 2023 Category: General Medicine Source Type: news
US approves postpartum depression pill
Clinical trials showed the drug helped to reduce depressive symptoms in as little as three days. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 5, 2023 Category: Consumer Health News Source Type: news
FDA OKs First Pill for Postpartum Depression
(MedPage Today) -- The FDA approved zuranolone (Zurzuvae) as the first oral treatment for postpartum depression, the agency announced late on Friday.
Until now, brexanolone (Zulresso) has been the only other treatment with an indication for postpartum... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 5, 2023 Category: Psychiatry Source Type: news
FDA approves first-ever pill for postpartum depression in new mothers
The Food and Drug Administration late Friday approved the first-ever pill that can be taken at home for postpartum depression. The medication, called zuranolone, and jointly developed by pharmaceutical companies Biogen Inc. BIIB, and Sage Therapeutics SAGE, , is taken daily for two weeks, the FDA…#biogeninc #fda #postpartum #tiffanyfarchione #divisionofpsychiatry #cdc #zuranolone #gaba #biogen (Source: Reuters: Health)
Source: Reuters: Health - August 5, 2023 Category: Consumer Health News Source Type: news
US FDA approves Biogen-Sage Therapeutics pill for postpartum depression
The U.S. Food and Drug Administration (FDA) on Friday approved Biogen (NASDAQ: ) and Sage Therapeutics' oral pill to treat postpartum depression (PPD (NASDAQ: )) in adults. The companies had sought the FDA's approval for the drug, Zurzuvae, to treat major depressive disorder (MDD), or clinical…#fda #biogen #zurzuvae #mdd #newdrugapplication (Source: Reuters: Health)
Source: Reuters: Health - August 5, 2023 Category: Consumer Health News Source Type: news
Postpartum depression drug developed by Sage, Biogen approved by FDA
A new depression drug has received the green light from the U.S. Food and Drug Administration after years of development by two Cambridge drugmakers. Zuranolone, a new drug co-developed by Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics Inc. (Nasdaq: SAGE), scored an FDA approval late Friday — but the approval was only for postpartum depression, not major depressive disorder. The companies had applied to market the drug as a treatment for both. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 5, 2023 Category: Biotechnology Authors: Rowan Walrath Source Type: news
FDA approves first oral drug for postpartum depression
It's estimated 1 in 7 women suffer from the condition after giving birth. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - August 5, 2023 Category: Consumer Health News Authors: David Ovalle Source Type: news
FDA Approves First Pill for Postpartum Depression FDA Approves First Pill for Postpartum Depression
An oral therapy could make far easier treating the condition, which affects roughly 500,000 women per year in the United States, the agency said.FDA Approvals (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - August 5, 2023 Category: Respiratory Medicine Tags: Ob/Gyn & Women ' s Health News Alert Source Type: news
There ’s Now An Oral Treatment for Postpartum Depression
Treating depression is complex and time-consuming, since matching patients to the right drug treatment is a matter of trial and error that can take weeks or even months. And post partum depression, which affects up to 20% of new mothers in the first six weeks after giving birth, is no different.
On August 4, the U.S. Food and Drug Administration (FDA) approved zuranolone, or Zurzuvae, for treating postpartum depression. The drug, developed by Massachusetts-based biotechs Sage Therapeutics and Biogen, is a pill that women take once a day for 14 days and is the first oral treatment for the major depressive condition.
[tim...
Source: TIME: Health - August 5, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news
FDA approves first oral treatment for postpartum depression
The Food and Drug Administration Friday approved a new hormone-based medication to treat postpartum depression, a condition that affects about 1 in 8 new mothers. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 5, 2023 Category: Consumer Health News Source Type: news
The first pill to treat postpartum depression has been approved by US health officials
Federal health officials have approved the first pill to specifically treat depression after childbirth (Source: ABC News: Health)
Source: ABC News: Health - August 5, 2023 Category: Consumer Health News Tags: Health Source Type: news
FDA approves first-ever pill for postpartum depression in new mothers
The Food and Drug Administration late Friday approved the first-ever pill that can be taken at home for postpartum depression. The medication, called zuranolone, and jointly developed by pharmaceutical companies Biogen Inc. BIIB, and Sage Therapeutics SAGE, , is taken daily for two weeks, the FDA…#biogeninc #fda #postpartum #tiffanyfarchione #divisionofpsychiatry #cdc #zuranolone #gaba #biogen (Source: Reuters: Health)
Source: Reuters: Health - August 5, 2023 Category: Consumer Health News Source Type: news
FDA approves first postpartum depression pill
Federal health officials have approved the first pill to specifically treat depression after childbirth. (Source: Reuters: Health)
Source: Reuters: Health - August 5, 2023 Category: Consumer Health News Source Type: news
Sage, Biogen postpartum depression pill zuranolone wins FDA approval
(Source: Reuters: Health)
Source: Reuters: Health - August 5, 2023 Category: Consumer Health News Source Type: news
The first pill to treat post-pregnancy depression will soon be available, after the Food and Drug Administration approved it
One in eight new mothers in the U.S. suffers from postpartum depression, according to the CDC, and some researchers say the rate might be higher. The first pill to treat post-pregnancy depression will soon be available, after the Food and Drug Administration approved it Friday.#cdc (Source: Reuters: Health)
Source: Reuters: Health - August 5, 2023 Category: Consumer Health News Source Type: news
